Life Insurance for a Medical Practice Buy-Sell Agreement: A Complete Guide

TL;DR. Life insurance is the mechanism that makes a medical-practice buy-sell agreement executable at a partner's death. The first decision is structural: cross-purchase, where each partner owns policies on the others, or entity-redemption, where the practice owns one policy per partner. The second is funding: term, permanent, or a split. The third is valuation: the face amount has to equal each partner's share of a refreshed practice valuation. In New York, the state estate-tax cliff near $7.16M and the Corporate Practice of Medicine doctrine together mean the funded buyout is not optional, it is structural.

Most medical-partnership buy-sell agreements we review have a contract in place and either no life insurance funding, or funding that was set at partnership formation and never refreshed. The contract creates the obligation; the insurance decides whether the obligation can be met. Roughly 40% of closely held businesses with buy-sell agreements use cross-purchase and about 35% use entity redemption, with the balance in hybrid or wait-and-see structures (American College of Trust and Estate Counsel, Business Planning, 2023). For a medical practice in New York, the structure choice interacts with state estate tax, federal tax treatment of the death benefit, and the Corporate Practice of Medicine doctrine that restricts practice ownership to licensed physicians. This guide walks through how each of those pieces fits together, starting with the structural choice.

Cross-purchase vs entity-redemption: how the two structures actually differ

Cross-purchase and entity-redemption are the two baseline structures for funding a buy-sell on death, and they differ on policy count, tax basis, and administrative complexity. Roughly 40% of closely held businesses use cross-purchase and 35% use entity-redemption (American College of Trust and Estate Counsel, Business Planning, 2023). The choice fundamentally shapes how many policies the partnership carries, whether surviving partners receive a tax basis step-up, and how administratively complex the arrangement becomes as the partnership grows.

Cross-purchase: each partner owns policies on the others

In a cross-purchase, each partner personally owns a life insurance policy on every other partner and is named as the beneficiary. When a partner dies, the surviving partners collect the death benefit tax-free under IRC §101(a), and each uses the proceeds to buy a proportional share of the deceased partner's interest directly from the estate. The surviving partners receive a cost-basis step-up equal to the purchase price, which reduces capital-gains exposure if the practice is later sold or a partner exits.

The structural cost is policy count. A two-partner practice needs two policies; a three-partner practice needs six; a four-partner practice needs twelve. The formula is N × (N-1). Above four partners the administrative load becomes the limiting factor, and a trusteed cross-purchase, where a single trustee holds one policy per partner on behalf of the others, compresses the policy count while preserving the basis step-up. The trusteed structure introduces its own transfer-for-value considerations that need to be addressed in the trust document.

Entity-redemption: the practice owns policies on each partner

In an entity-redemption, the professional corporation or PLLC owns one policy on each partner, pays the premiums, and receives the death benefit. On a partner's death, the practice uses the proceeds to redeem the deceased partner's interest from the estate. The surviving partners' ownership percentages expand proportionally, but their cost basis in the practice does not step up.

Policy count is the operational advantage: one policy per partner regardless of partnership size. The trade-off is the lost basis step-up, which matters most when the surviving partners later sell the practice. For C-corporation professional practices, the death benefit can also trigger corporate alternative minimum tax; for S-corporations and entities taxed as partnerships, the pass-through treatment is generally cleaner. Most NY medical PLLCs are pass-through, which simplifies the analysis.

Hybrid and trusteed structures

A hybrid or wait-and-see structure lets the partnership defer the choice until the death occurs, with both the practice and the surviving partners named as eligible buyers in a stated order of priority. The trusteed cross-purchase compresses policy count by using a single trustee-held policy set. Both are common above three partners and both need careful drafting to avoid tripping the transfer-for-value rule or attributing incidents of ownership to the insured. The practice's tax counsel drives the selection; the insurance broker drives the funding math once the structure is chosen.

NY-specific tax and ownership rules that shape the structure

New York medical partnerships operate under two state-specific constraints that federal-only analysis misses: the NY estate-tax cliff near $7.16M in 2026 and the Corporate Practice of Medicine doctrine that limits practice ownership to licensed physicians. The 2026 NY basic exclusion is approximately $7.16 million per individual, and once an estate exceeds it by more than 5% the exclusion phases out entirely (NY Department of Taxation and Finance, Estate Tax, 2026). For physician partners at peak career value, both rules actively shape how the buy-sell is structured.

The NY estate-tax cliff

New York's estate tax runs on a separate schedule from federal, with a 2026 basic exclusion near $7.16M that phases out entirely once the estate exceeds 105% of the exclusion. The federal exclusion in 2026 sits near $13.99M (Internal Revenue Service, Estate Tax, 2026). For a physician partner whose practice equity plus personal assets land near $7.5M, the NY cliff can pull the entire estate into taxation at the top NY rate, while the federal estate would still be fully under the exclusion. The structuring goal for partners near the cliff is to keep the life insurance death benefit out of the insured's taxable estate so it does not push the estate over the NY edge.

The Corporate Practice of Medicine doctrine

New York restricts ownership of a medical professional corporation or PLLC to licensed physicians under Education Law §§6521–6531 and Business Corporation Law §1503 (NY Senate, Education Law Article 131, current). A deceased physician's non-physician spouse or adult child cannot legally hold the practice interest, even through inheritance. Practically, this means the buy-sell agreement must trigger on death, and the surviving physician partners or the practice itself must acquire the interest promptly. The law does not give the estate the option to hold the interest while a buyout is negotiated; the transfer has to happen.

Trust-owned policies to solve the NY cliff

For partners whose estates sit near the NY exclusion, an irrevocable life insurance trust (ILIT) can own a portion of the coverage outside the insured's estate entirely under NY Estates Powers and Trusts Law (NY Senate, Estates Powers and Trusts Law, current). The ILIT owns the policy, pays the premium from annual exclusion gifts by the insured, and receives the death benefit. The trustee then either purchases the practice interest from the estate under the buy-sell or provides estate liquidity for tax obligations. The ILIT analysis requires careful drafting so the trust beneficiaries' interests align with the partnership's acquisition mechanics, and any transfer of an existing policy into the trust has to clear the transfer-for-value rule.

Practice valuation: how the life insurance face amount is set

The life insurance face amount should equal each partner's proportional share of an agreed practice valuation, and the most common failure mode is a valuation that was set at partnership formation and never refreshed. Medical practice valuations typically run 0.5x to 1.0x annual net collections for primary care and 1.0x to 2.0x for specialty and procedure-heavy practices, with meaningful variance by geography, payer mix, and ancillary revenue (American Medical Association, Physician Practice, 2023). The buy-sell agreement should specify the valuation method, the refresh cadence, and the party responsible for initiating each update.

Four valuation methods in routine use

Capitalization of earnings discounts projected practice earnings by a capitalization rate that reflects risk and growth; this is the most technically defensible method and the one credentialed appraisers use most often. A multiple of net collections applies an industry multiple to the trailing twelve months of collections; simpler, but it can overstate value for practices with significant non-operating revenue. Book value measures assets minus liabilities and understates any going concern; it is generally useful only as a floor. Independent appraisal brings in a credentialed valuation professional on a stated cadence, with fees typically running $5,000 to $25,000 depending on practice size.

Why the IRS §2703 safe harbor requires a real valuation

IRC §2703 governs whether the price set by a buy-sell agreement is respected for estate-tax purposes (Internal Revenue Service, IRC Code and Publications, current). A buy-sell price is respected as the estate-tax valuation when the agreement is a bona fide business arrangement, not a device to transfer to family members for less than full consideration, and the terms are comparable to arms-length arrangements. A token valuation set once at partnership formation and never revisited does not satisfy the comparability test. Partnerships that want the buy-sell price to control for estate-tax purposes need a valuation method with a refresh cadence and a credentialed appraiser on record.

Cadence: every three years at minimum

The standard refresh cadence is every three years, with many sophisticated agreements specifying an annual review against year-end financials. The insurance face amounts adjust at each refresh, with new policies issued or existing face amounts stepped up. For policies written with guaranteed insurability riders, the insurability rider can be exercised at the refresh without new medical underwriting, which is the cleanest path to keeping coverage aligned with practice value over a 20-year partnership horizon.

Funding: term, permanent, or a split-funded approach

Term life is cheaper than permanent; permanent builds cash value but costs three to five times more at comparable face amounts. The right structure for a long-horizon medical partnership is usually a split. Term premiums for a healthy 40-year-old physician typically run 5 to 15 cents per $1,000 of face amount per year on a 20-year level term, while permanent coverage at the same face amount runs 1 to 2 dollars per $1,000 annually in the early policy years (Society of Actuaries, Experience Studies, 2023). The cost spread is what drives the split-funded approach most NY medical partnerships settle on.

Term: cheap, but mismatched to a partnership that outlives the term

A 20-year level term policy on a 40-year-old partner expires when the partner is 60. If the partnership continues past that point, the coverage ends precisely when mortality risk is rising and the need is still live. Renewal term at that age carries premiums several multiples of the original, often ten times or more, and coverage is frequently declined for health reasons that did not exist at original issue. Term alone is rarely the right answer for a medical partnership expected to continue past the term period.

Permanent: expensive, but it persists

Permanent coverage, whether whole life or universal life, remains in force for the partner's lifetime, so coverage is there regardless of when the partner dies or retires. The premium is the cost. For a four-partner medical practice each insured at $1M of permanent coverage, annual premiums can run $25,000 to $60,000 per partner at middle ages, which is material on a practice operating budget. Permanent also builds cash value that can be accessed through loans or surrenders if the partnership structure changes, which adds flexibility at the cost of added complexity around policy ownership.

Split-funded: term for the working years, permanent for the tail

The working approach for most medical partnerships is a split. Term insurance covers the bulk of the buyout face amount for the years partners are actively practicing and the buy-sell is most likely to trigger on death during working years. A smaller permanent layer, typically 20% to 40% of the total face amount, covers the long-tail scenario where a partner continues to hold an interest past the term expiry, often into a phased retirement or extended partial practice. The split keeps annual premium load reasonable while eliminating the coverage cliff at age 60. When the permanent layer is issued with guaranteed insurability riders, face amounts can be raised at valuation refreshes without new medical underwriting.

Tax treatment: IRC §101, §2042, and the transfer-for-value trap

The death benefit itself is generally exempt from federal income tax under IRC §101(a), but estate-tax inclusion under IRC §2042 and the transfer-for-value rule at §101(a)(2) are the two provisions most likely to cost a medical partnership money when the structure is wrong. The federal estate-tax exemption in 2026 is approximately $13.99 million per individual, and the New York exemption is roughly $7.16 million with the cliff phaseout (Internal Revenue Service, Estate Tax, 2026). Each structure's tax posture should be reviewed by the practice's CPA before the agreement is executed and before any restructuring is attempted.

IRC §101(a): the income-tax exemption on the death benefit

Death benefits paid under a life insurance contract are generally exempt from federal income tax under IRC §101(a). For a cross-purchase buy-sell, this means the surviving partners receive the proceeds tax-free and use them to purchase the deceased partner's interest from the estate. For an entity-redemption, the practice receives the proceeds tax-free and uses them for the redemption. The exemption is load-bearing: without it, the buy-sell mechanics would lose roughly a third of the proceeds to federal income tax before the buyout closed.

IRC §2042: incidents of ownership and estate-tax inclusion

IRC §2042 includes the life insurance death benefit in the insured's gross estate when the insured holds "incidents of ownership" in the policy at death. Incidents include the power to change the beneficiary, surrender the policy, borrow against it, or assign it. Under a cross-purchase, the other partners own the policy on the insured, which keeps the insured out of §2042 inclusion cleanly. Under an entity-redemption, the practice owns the policy; if the insured partner is also a controlling shareholder or officer, §2042(2) can attribute corporate incidents of ownership to the insured personally. The attribution analysis is fact-specific and matters most for partners near the NY estate-tax cliff.

IRC §267 and the transfer-for-value trap on restructuring

IRC §101(a)(2) states that if a life insurance policy is transferred for valuable consideration, the death benefit becomes taxable as ordinary income to the recipient, to the extent it exceeds the consideration paid plus subsequent premiums. Statutory safe harbors protect transfers to the insured, to a partner of the insured, to a partnership in which the insured is a partner, or to a corporation in which the insured is a shareholder or officer. The trap arises when a partnership restructures from cross-purchase to entity-redemption, or vice versa, and policies are reassigned between parties without confirming that the new ownership falls inside a safe harbor. A policy transferred to an unrelated party, or to a partnership in which the insured is not a partner, can lose the entire income-tax exemption on the death benefit. Any restructuring should be reviewed by tax counsel before policy ownership changes, and the §267 related-party rules should be mapped alongside the §101(a)(2) safe-harbor analysis.

Policy structuring: owner, beneficiary, premium-payor, and the Goodman triangle

The mechanical choices about who owns the policy, who pays the premium, and who receives the death benefit decide whether the proceeds arrive where the buy-sell intends and whether any portion is pulled into the insured partner's taxable estate or gift-tax exposure. The Goodman triangle is the classic trap: when the policyowner, insured, and beneficiary are three different parties, the IRS can treat the death benefit as a taxable gift from the owner to the beneficiary. For physicians with estate-tax exposure, particularly near the NY cliff, keeping the triangle collapsed into a two-party structure is load-bearing. The 2026 federal annual gift-tax exclusion is approximately $19,000 per recipient (Internal Revenue Service, Gift Tax, 2026).

Clean cross-purchase structure

In a clean cross-purchase, each partner is the owner, premium-payor, and beneficiary on every policy they hold on the other partners. The insured is a separate party, but they are not a leg of the Goodman triangle because the owner and beneficiary are the same person. The insured has no incidents of ownership, no premium obligation, and no role in the contract beyond being the insured life. At death, the surviving partners collect the proceeds directly as the named beneficiaries and the proceeds sit outside the deceased partner's estate under §2042.

Clean entity-redemption structure

In a clean entity-redemption, the practice is the owner, premium-payor, and beneficiary on each partner's policy. The insured partner is the insured life but not an owner or beneficiary. The death benefit is received by the practice, which then redeems the deceased partner's interest from the estate. The estate receives the redemption proceeds, not the insurance proceeds directly, which is the structural reason this arrangement keeps the death benefit out of the insured's estate so long as the insured does not hold attributable corporate control under §2042(2).

ILIT ownership for estate-tax purposes

For partners whose estates exceed the NY exclusion or approach the federal exclusion, an irrevocable life insurance trust owns the policy as a separate legal entity. The ILIT is the owner, premium-payor, and beneficiary; the insured makes annual exclusion gifts to the trust to fund the premiums. The death benefit is received by the trustee, who then coordinates with the buy-sell either by purchasing the practice interest from the estate at fair market value or by providing estate liquidity for estate-tax obligations. The ILIT drafting needs to align the trust beneficiaries' interests with the partnership's acquisition mechanics, and any transfer of an existing policy into the trust has to clear the §101(a)(2) transfer-for-value analysis.

Avoiding the Goodman triangle at restructuring

The Goodman triangle most often appears at restructuring, when a partnership shifts from one buy-sell structure to another and someone changes the beneficiary designation without also changing the owner, or pays a premium on a policy they do not own for a life they are not the beneficiary of. Any structural change to a buy-sell's policy ownership should map the owner, insured, beneficiary, and premium-payor for each policy before and after the change, and confirm that each policy still sits as a two-party arrangement at the end. A single policy with three different parties on the three roles is the mistake to watch for.

Reviewing the life insurance layer alongside the rest of the partnership plan

A funded buy-sell is one layer of a physician partner's financial plan, and it sits alongside the personal disability coverage that protects the individual partner's income, the practice's own operating coverage, and each partner's personal estate plan. Our companion Insight on physician life insurance and partnership buy-sell funding walks through the funding-layer decisions in more operational detail, and our Guide to own-occupation disability insurance for physicians addresses the individual-income side of the protection plan. For partners still in training, the residency and fellowship insurance checklist covers the coverage choices set at the earliest underwriting window. Practices thinking about benefits that help retain partner-track physicians should read our piece on practice benefits and physician retention, and the parallel Insight on student loan protection under physician disability coverage closes the education-debt loop. For NY medical practices evaluating malpractice alongside the partnership structure, the NY medical malpractice insurance guide sets the regulatory context. Service-level information on the life insurance review process lives on our personal life insurance overview, and the personal disability insurance page describes how the disability review fits alongside this work. The physicians industry page sets the broader NY practice context. If you want to walk through an existing buy-sell and the funding layer together, you can schedule a consultation at a time that works for you.